Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michela Dargenio
Every‐other‐day Palonosetron Plus Aprepitant for Prevention of Emesis Following Induction Chemotherapy for Acute Myeloid Leukemia: A Randomized, Controlled Study From the “Rete Ematologica Pugliese”
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Related publications
Immunologic Consequences of Chemotherapy for Acute Myeloid Leukemia
Journal of Pediatric Hematology/Oncology
Child Health
Oncology
Pediatrics
Hematology
Perinatology
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron?
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Micafungin Prophylaxis for Acute Leukemia Patients Undergoing Induction Chemotherapy
BMC Cancer
Cancer Research
Oncology
Genetics
Elderly Do Benefit From Induction Chemotherapy: High Dose Mitoxantrone Based (“5+1”) Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia
American Journal of Hematology
Hematology
Crude Coal Tar Treatment Every Day Versus Every Other Day for Plaque Psoriasis
Acta Dermato-Venereologica
Dermatology
Medicine
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
Clinical Hematology International
Efficacy of the Combination Use of Aprepitant and Palonosetron for Improving Nausea in Various Moderately Emetogenic Chemotherapy Regimens
BMC pharmacology & toxicology
Medicine
Pharmacology
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
Post-Remission Strategies for the Prevention of Relapse Following Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia: Expert Review From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation
Transplantation
Hematology
